Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients. Horvath A, Farkas A, Reti I, Ilyes N, et al. Respir Med 2025;236:107916.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Horvath A, Farkas A, Reti I, Ilyes N, et al. Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients. Respir Med 2025;236:107916.
PMID: 39701396